As SARS-CoV-2 moves fast through our global population, the pharmaceutical industry faces tremendous pressure to move even faster.
Press Release
March, 2020 - /3BL Media/ - Industry leaders are jousting with questions of how to quickly evaluate new and repurposed drugs while simultaneously readying their operations for rapid transformation. Novel partnerships between private R&D teams and public health agencies are emerging to address the “discovery” half of that equation, which leaves company leaders to grapple with the other half: how can they prepare their operations for commercial-scale manufacturing of a therapy that hasn’t yet been identified or approved?
Nearly one month ago, together with Creator David Clark Cause and in partnership with United Nations Human Rights and the Linux Foundation, we announced climate change as the theme for the 2020 Call for Code Global Challenge. In that brief period, much has changed. COVID-19 (Coronavirus) has spread across the world with unprecedented effect and now has the potential to become the greatest crisis of modern times.
At IBM, I have the privilege of working with colleagues who have dedicated their lives and careers to advancing science and creating innovative technology that can be a force for progress in the world. Since the start of the COVID-19 pandemic we have been working closely with governments in the U.S.
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
Press Release
EDCTP grants the PAMAfrica research consortium €21.9 million over a 5 year period; MMV, Novartis and other partners will provide an additional €22 million.
The PAMAfrica consortium brings together a global medicines company, a not-for-profit product development partnership and leading academic institutions in Africa and Europe. PAMAfrica aims to develop new medicines for both severe and uncomplicated malaria, designed to combat emerging artemisinin resistance.
The projects will include development of the first new malaria treatment for babies under 5 kg, a new fast-acting medicine for the treatment of severe malaria, and new combinations to treat drug-resistant uncomplicated malaria.
The early data results seemed almost too good to be true.
That's what Sen Zhuang, M.D., Ph.D., Vice President, Oncology Clinical Research, Janssen Research & Development, was thinking at a meeting of the American Society of Clinical Oncology (ASCO) last summer.
A new report from the American Cancer Society sheds light on declining death rates from cancer—especially lung cancer. We asked an expert on the disease to break down the data, and share what's to come in better detecting and preventing it.
Article
A new report from the American Cancer Society sheds light on declining death rates from cancer—especially lung cancer. We asked an expert on the disease to break down the data, and share what's to come in better detecting and preventing it.
By Douglas Brooks, Executive Director, Community Engagement at Gilead
Blog
Every now and then, I allow myself to revisit a time when I feared hearing the phone ring. That such an ordinary occurrence could induce deep emotion reflected the environment in which many of us resided. Knowing that the call could easily be the news of another friend having died or having been rushed to the hospital sometimes froze me in place.
By Diana Brainard, MD, Senior Vice President for HIV and Emerging Viruses at Gilead
Blog
When I was a medical student in the mid-1990s, the scope and impact of the HIV/AIDS epidemic was devastating and there was little hope for long-term survival. During rotations at Charity Hospital in New Orleans, I observed people living with HIV demonstrate courage, as well as numerous healthcare professionals providing compassionate care.
It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.
Article
It's the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.
Partnership with Susan G. Komen includes donation of padding at 3-Day events
Multimedia with summary
Mohawk Flooring is proud to support Susan G. Komen and help the fight against breast cancer. Through the partnership, more than $6.1 million has been raised to fund research for treatment.
